1. Which of the following therapies should generally not be used to treat feline hyperthyroidism?
A. Carbimazole
B. Methimazole
C. Propylthiouracil
D. Radioactive iodine-131
2. Which of the following statements regarding the use of methimazole in cats with hyperthyroidism is correct?
A. Carbimazole is a suitable alternative treatment for cats who do not tolerate methimazole therapy.
B. Methimazole is not approved in the United States, so dosage forms for cats must be compounded.
C. The onset of effect is much faster when methimazole is administered transdermally, compared with oral administration.
D. Up to 15% of cats experience a hypersensitivity reaction that manifests as facial excoriations and necessitates discontinuation of therapy.
3. Which of the following insulins approved for use in humans also is used commonly in the treatment of diabetes in cats?
A. Insulin detemir
B. Insulin glargine
C. Insulin glulisine
D. Insulin lispro
4. Which of the following statements regarding diabetes mellitus in cats is true?
A. Blood samples for home glucose testing should be taken from the cephalic vein.
B. Glipizide is a highly effective long-term oral therapy for feline diabetes.
C. It is not unusual for feline diabetes to go into spontaneous clinical remission within 1 to 4 months after treatment is initiated.
D. Most cats with diabetes have type 1 diabetes and require therapy with insulin.
5. Which of the following statements regarding feline hypertrophic cardiomyopathy and its treatment is correct?
A. Many cats are completely asymptomatic until they are diagnosed or experience sudden death.
B. Most cases of feline hypertrophic cardiomyopathy occur in female cats.
C. Pimobendan is used frequently in cats, in part because of ease of administration of the FDA-approved veterinary dosage form (which helps to decrease stress).
D. Spironolactone is the diuretic of choice in cats because of strong evidence of efficacy.
6. You receive a prescription from a veterinarian for diltiazem 45 mg PO q24h for a 4.5-kg cat with cardiomyopathy. Which of the following products should be used as the source of active ingredient, to provide the requested dose and frequency of administration?
A. Cardizem CD 120 mg capsules (controlled delivery).
B. Dilacor XR 180 mg capsules (extended release).
C. Dilacor XR 240 mg capsules (extended release).
D. Diltiazem 30 mg tablets (immediate release).
7. Which of the following statements regarding feline asthma is correct?
A. Feline asthma is considered to be reversible if known triggers are removed from the environment.
B. Feline asthma is one of the most common disorders in older cats.
C. Leukotriene inhibitors are a mainstay of therapy for cats with asthma.
D. The AeroKat spacer and mask is designed specifically for use in cats with asthma.
8. Which of the following pairs represent the anti-inflammatory agent and rescue bronchodilator of choice for feline asthma?
A. Cyclosporine and terbutaline
B. Fluticasone and albuterol
C. Prednisolone and salmeterol
D. Prednisone and theophylline
9. Which of the following therapeutic agents should never be used in a cat with feline lower urinary tract disease?
A. Amitriptyline
B. Phenazopyridine
C. Phenoxybenzamine
D. Prazosin
10. Which of the following statements regarding management of feline lower urinary tract disease (FLUTD) is correct?
A. In contrast with many other conditions that affect cats, all of the drug therapies used to treat FLUTD are FDA-approved for use in cats.
B. In households that have more than cat, owners should be encouraged to provide one litter box per cat plus one additional box.
C. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used most frequently for analgesia in cats with FLUTD.
D. Urinary tract infection is the most common cause of FLUTD in cats younger than 10 years of age.
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Will the information presented cause you to change your practice?
A. Yes
B. No
23. Are you committed to making these changes?
A. Yes
B. No
24. As a result of this activity, did you learn something new?
A. Yes
B. No
25. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
26. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20